 quality-of-life-adjust evalu adjuv therapi oper breast cancer intern breast cancer studi group object singl cycl adjuv chemotherapi durat chemotherapi premenopaus women chemoendocrin therapi postmenopaus women oper breast cancer quality-of-life-ori end point q-twist quality-adjust analysi twist time symptom toxic design multicent clinic trial intern breast cancer studi group ibcsg ludwig group trial set ibcsg center sweden switzerland australia yugoslavia spain new zealand itali germani south africa patient data avail elig patient node-posit breast cancer adjuv treatment total mastectomi axillari clearanc intervent patient singl cycl periop chemotherapi consist cyclophosphamid methotrex fluorouracil leucovorin cycl month chemotherapi cyclophosphamid methotrex fluorouracil prednison premenopaus women combin tamoxifen postmenopaus women periop chemotherapi cours adjuv therapi result year median follow-up patient durat therapi disease-fre surviv percentag overal surviv percentag singl periop cycl year burden toxic effect durat treatment superior control diseas year follow-up time adjuv treatment toxic patient averag month q-twist durat therapi singl cycl gain premenopaus patient month gain postmenopaus women month conclus month adjuv chemotherapi chemoendocrin therapi quantiti qualiti life patient node-posit breast cancer singl short cours periop combin chemotherapi